Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Learning and Development
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Multi-site collaboration for precision prostate cancer care

Multi-site collaboration for precision prostate cancer care

Stories Nov 15, 2023 3 minutes

Several research teams are investigating new genome sequencing research headquartered in Vancouver to supercharge the discovery of tailored treatments.

Researchers at the Vancouver Prostate Centre are leading a multi-site clinical trial to explore new precision treatments for patients with prostate cancer. The Genomic-biomarker-selected Umbrella Neoadjuvant Study (GUNS) trial led by Vancouver Coastal Health Research Institute (VCHRI) researchers Dr. Lucia Nappi and principal investigator Dr. Martin Gleave will use genomic markers from study participant samples to make treatment recommendations for patients.

“We are incredibly excited about the potential for GUNS to enhance patient outcomes through a deeper understanding of prostate cancer drivers and treatment effectiveness,” states Gleave. “While our initial focus is on DNA and RNA sequencing, we anticipate that additional branches of this research will be introduced as novel discoveries to enhance patient care are made.” 

Dr. Martin Gleave is a surgeon-scientist and distinguished professor and chairman of the Department of Urologic Sciences at the University of British Columbia (UBC). He co-founded and directs the Vancouver Prostate Centre, a UBC-VCHRI National Centre of Excellence.

An evolving area of research, precision medicine is focused on personalizing treatments by using genomic and molecular profiling to identify unique gene changes in individuals and cancer tumours. Clinicians draw from published research, such as the anticipated peer-reviewed publications from the GUNS clinical trial, to help select the most promising therapy for disease suppression or eradication and to support patient recovery. 

Both DNA and RNA are found in every living cell. DNA is the microscopic double helix composed of two chains of the bonded molecules adenine, guanine, cytosine and thymine. RNA mainly acts as a messenger between DNA and the creation of proteins. 

“Currently, very few data sets on prostate cancer pathology include both DNA and RNA sequencing analysis,” says Nappi. Seeing prostate cancer cells at the genomic level gives researchers a fine-grained view of the inner-workings of the disease.

“The molecular profiling used in this study to view prostate cancer cells is similar to the image detail you can see on a high-definition television screen, compared to a regular television screen.”

Mutations within DNA or RNA can increase a person’s risk of developing different types of prostate cancer. These are also present within cancer, which is why sequencing — or using advanced technology to examine the microscopic characteristics of DNA or RNA — can reveal important information in prostate cancer pathology and treatment effects. 

Tailoring care at the genomic level

GUNS participants all have high- or very high-risk prostate cancer localized to the prostate only. All patients are screened at the outset of the trial based on a biopsy of their prostate cancer. 

For the first eight weeks of the study, participants receive blood tests and androgen deprivation therapy — androgens are hormones that promote prostate cancer growth. Following the sequencing of their DNA, participants will be allocated to one out of four treatment streams. 

“For example, if a participant’s prostate cancer has a genomic profile suggesting high dependence on the androgen receptor pathway, we will place them in the treatment stream designed to maximize their androgen inhibitor therapy,” notes Nappi. “This treatment involves two oral medications and one injection medication that targets the same androgen receptor pathway.”

“On the other hand, if we find genes in a participant’s prostate cancer that are associated with a poorer response to hormone therapy, or a more aggressive form of prostate cancer, we will place the participant in the stream that receives hormone therapy in combination with either immunotherapy or chemotherapy.”

Dr. Lucia Nappi is a clinician scientist and medical oncologist, as well as a senior research scientist with the Vancouver Prostate Centre and assistant professor in the Faculty of Medicine at UBC.

At the conclusion of the trial, participants will receive a radical prostatectomy — the removal of the prostate gland and surrounding lymph nodes. 

“The DNA and RNA analysis of the whole excised prostate after the trial will help us see how the treatment streams affected each patient’s prostate cancer, providing an extra layer of detail to our investigation.” 

“The tumour samples taken before and after the trial will give us a more detailed and bigger picture view of: why treatments may or may not have worked, molecular pathways that could lead to treatment resistance and possible opportunities to enhance treatment effectiveness,” says Nappi.

In the coming years, the GUNS research study is expected to extend into the United States, with the potential for global expansion.

 

Researchers

Martin Gleave
Lucia Nappi

Related Articles

Cancer driver discovery opens up treatment pathways for rare pediatric disease

Transforming cervical cancer care

Computer-aided detection and diagnosis of colorectal cancer

Share:

  • Facebook
  • Linkedin
  • X
  • Email

Related Research Centres/Programs

Vancouver Prostate Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Vancouver Coastal Health Research Institute is among Canada’s leading hospital-based research institutes

Dec 7, 2023 award
Type
Participate in Research

Gambling’s dopamine pathway to addiction

Dec 3, 2023 participate, addiction, brain
Type
Stories

Celebrating a year of research progress and unity

Dec 1, 2023 seasonal, global health
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • X
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy